Cushman & Wakefield (NYSE:CWK – Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Cushman & Wakefield to announce earnings of $0.3577 per share and revenue of $2.78 billion for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.
Cushman & Wakefield (NYSE:CWK – Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.35 EPS for the quarter. The firm had revenue of $2.76 billion for the quarter. Cushman & Wakefield had a return on equity of 15.90% and a net margin of 0.64%. On average, analysts expect Cushman & Wakefield to post $1.45 EPS for the current fiscal year and $1.63 EPS for the next fiscal year.
Cushman & Wakefield Price Performance
Shares of NYSE:CWK opened at $14.29 on Tuesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.08 and a current ratio of 1.08. The business’s fifty day moving average price is $12.54 and its two-hundred day moving average price is $13.40. The stock has a market cap of $3.35 billion, a PE ratio of 49.28 and a beta of 1.50. Cushman & Wakefield has a one year low of $10.88 and a one year high of $17.40.
Insiders Place Their Bets
In other news, insider Laurida Sayed sold 16,000 shares of Cushman & Wakefield stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $13.88, for a total value of $222,080.00. Following the completion of the sale, the insider owned 5,461 shares of the company’s stock, valued at $75,798.68. The trade was a 74.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nathaniel Robinson sold 12,500 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $13.39, for a total value of $167,375.00. Following the completion of the transaction, the insider owned 58,376 shares of the company’s stock, valued at $781,654.64. The trade was a 17.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.74% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on CWK shares. Weiss Ratings upgraded Cushman & Wakefield from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 6th. Citizens Jmp dropped their price objective on Cushman & Wakefield from $19.00 to $16.00 and set a “market outperform” rating for the company in a research report on Thursday, October 22nd. Zacks Research cut Cushman & Wakefield from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Citigroup reissued a “market outperform” rating on shares of Cushman & Wakefield in a research note on Thursday, October 22nd. Finally, Barclays boosted their target price on shares of Cushman & Wakefield from $15.00 to $16.00 and gave the company an “equal weight” rating in a research note on Monday, August 17th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Cushman & Wakefield presently has an average rating of “Hold” and a consensus price target of $16.57.
View Our Latest Stock Analysis on CWK
About Cushman & Wakefield
Cushman & Wakefield plc (NYSE: CWK) is a global commercial real estate services company that provides advisory, transaction, and property-related solutions to property owners, occupiers, investors, and developers. The company serves clients across office, industrial, retail, multifamily, hospitality, and other real estate sectors.
Its services include leasing and tenant representation, capital markets and investment sales, valuation and advisory, property and facilities management, project and development services, and workplace and portfolio consulting.
Read More
- Five stocks we like better than Cushman & Wakefield
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Cushman & Wakefield Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cushman & Wakefield and related companies with MarketBeat.com's FREE daily email newsletter.
